IL17A and cancer: In our previous studies, DEB-TACE had a positive antitumor performance in patients with malignant tumors, with changes in the microenvironment including increased natural killer cells and CD4+/CD8+ ratios, and decreased levels of T regulatory cells and interleukin-17A (35, 36).